Message Font: Serif | Sans-Serif
No. of Recommendations: 1
Looks like a tough day ahead for shares of GILD, which are currently trading down about $22 from yesterday's close.

The FDA has received a recommendation from an expert panel to deny approval of Gilead's experimental AIDS drug, Adefovir.

" The panel's 13-1 vote marks the first time an FDA panel has refused to back a drug for HIV. Panel members said the company hadn't proven the drug, called adefovir, to be potent enough to outweigh its known risk of triggering kidney damage. "

TMF Jeanie
Print the post  


What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.